Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDCO 216

Drug Profile

MDCO 216

Alternative Names: AIM; ApoA1 Milano; ESP-24217; ET-216; ETC-216; MDCO-216; r-ApoA-I Milano; rApoA-IM; rApoA-IM protein (dimer)

Latest Information Update: 30 Nov 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Esperion Therapeutics; The Medicines Company
  • Class Ischaemic heart disorder therapies; Phosphatidylcholines; Phospholipids
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes; Coronary artery disease; Coronary artery restenosis

Most Recent Events

  • 07 Nov 2016 Discontinued - Phase-I for Coronary artery disease in USA due to lack of effficacy (IV)
  • 07 Nov 2016 Discontinued - Phase-II for Acute coronary syndromes in Canada, Czech Republic, Netherlands, Poland, Hungary and USA due to lack of effficacy (IV)
  • 26 Oct 2016 The Medicines Company initiates the phase II MILANO DRIVE trial for Acute coronary syndromes in Hungary (IV, Infusion) (EudraCT2014-005462-30)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top